A retrospective study presented at the American Society of Clinical Oncology 2025 annual meeting evaluated women with endometrial neuroendocrine tumors and found that adjuvant treatment with...
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
The results of a large retrospective analysis noted significant age-related differences in the germline landscape of endometrial cancer. This study was presented as a poster at the 2025 American Society of...
A phase 2 study evaluating the safety and efficacy of letrozole, abemaciclib, and metformin in treating estrogen receptor–positive recurrent endometrial cancer highlights promising outcomes in a select...
A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
In the RUBY trial, dostarlimab combined with chemotherapy delayed quality of life deterioration across multiple domains in patients with advanced or recurrent endometrial cancer, particularly in those with...
